6505--770-24-4-801-0686 -National CMOP CLINDAMYCIN -(VA-24-00096153)
ID: 36C77024Q0380Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNATIONAL CMOP OFFICE (36C770)LEAVENWORTH, KS, 66048, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/2081bdb14d9b42e995f36e37c1cfcccf/view
Timeline
    Description

    The Department of Veterans Affairs is seeking qualified vendors to provide Clindamycin PO4 1% Top Swab for delivery to multiple Compounding Medication Outpatient Pharmacies (CMOP) across the country. This procurement aims to secure approximately 3,584 units of the specified pharmaceutical product, ensuring compliance with federal regulations and the Drug Supply Chain Security Act (DSCSA). The goods are essential for the VA's healthcare services, supporting the treatment of various medical conditions. Interested vendors must submit their quotations by September 6, 2024, including a signed SF1449 cover page, a price schedule, proof of a valid State Wholesale Distributor License, and a Buy American Act Certificate. For further inquiries, vendors can contact Kelley Cunningham at kelley.cunningham@va.gov or call 913-684-0140.

    Point(s) of Contact
    Kelley CunninghamContact Specialist
    (913) 684-0140
    kelley.cunningham@va.gov
    Files
    Title
    Posted
    36C77024Q0380_1.docx
    The document outlines a government procurement solicitation by the Department of Veterans Affairs for pharmaceutical supplies targeting the National Consolidated Mail Outpatient Pharmacy (CMOP). It includes critical details such as solicitation number (36C77024Q0380), award details, and submission requirements for vendors. Key components consist of required deliverables (six line items of chemicals), specific shipping terms, compliance with strict barcoding standards, and the need for all products to be ship-compatible with USPS. Vendors must provide details like valid National Drug Codes (NDCs) for each product and adhere to the terms stated in the FAR and VAAR clauses. Additional requirements include a firm commitment regarding product availability, return provisions for nonconforming products, and completion of certain certifications related to the Drug Supply Chain Security Act. Invoicing instructions specify electronic submission facilitated by the VA's payment systems, ensuring timely processing. The purpose is to ensure the procurement of compliant and quality pharmaceutical products for the VA while fostering participation from small businesses and adhering to federal regulations and standards. This RFP reflects a structured approach to managing healthcare contracts efficiently, emphasizing both legal compliance and operational requirements.
    36C77024Q0380.docx
    The Department of Veterans Affairs (VA) plans to solicit bids for procuring Clindamycin PO4 1% Top Swab for delivery to multiple Compounding Medication Outpatient Pharmacies (CMOP) across the country. This presolicitation notice outlines the requirements for the solicitation number 36C77024Q0380, which is set aside for small businesses. The contract includes detailed quantities and packaging needs for multiple CMOP facilities, specifying a total of approximately 3,584 units across six locations. The estimated issue date for the request for quotation (RFQ) is September 3, 2024, with responses due by September 6, 2024. Vendors must submit quotations via email, including essential documentation such as a signed solicitation cover page (SF1449), a price schedule, a valid state wholesale distributor license, and a Buy American Act Certificate, verifying compliance with drug supply regulations. The document emphasizes that all responsible sources may submit a quotation, further encouraging transparency and competition among small businesses in the pharmaceutical sector. Compliance with the Drug Supply Chain Security Act (DSCSA) is mandatory for bidders.
    S02_Pricing Schedule_Q0380.xlsx
    The CMOP National RFQ 36C77024Q0380 is a solicitation for vendors to provide specific pharmaceutical and medical surgical supplies, with bids due by September 6, 2024, at 3:00 PM CT. Vendors must submit a signed SF1449 cover page, a quote spreadsheet, proof of a valid State Wholesale Distributor License, and a Buy American Act certificate. Each vendor can submit only one quote and must note any discrepancies between proposed and listed National Drug Codes (NDC) in the "Vendor Comments" section. Critical to this request is the stipulation that all products must have at least one year until expiration at the time of delivery. The document outlines various line items with specific requirements, including product descriptions, quantities, and pricing for items like Clindamycin Po4 1% Top Swab. The receipt of quotes is directed to a specific email address for further processing. This RFQ exemplifies a structured procurement process aimed at acquiring necessary medical supplies while ensuring compliance with federal regulations and guidelines.
    Similar Opportunities
    770-25-1-801-0134 -National CMOP ZINC OXIDE OINT
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Zinc Oxide Ointment as part of a contract with the National CMOP Office. Vendors are required to supply varying quantities of this pharmaceutical product, ensuring compliance with federal regulations, including the Drug Supply Chain Security Act and FDA approval. The ointment will be delivered to multiple VA CMOP facilities, with a total requirement exceeding 5,000 units, and must be shipped within 10 days of order receipt. Interested vendors must submit their proposals by December 30, 2024, at 4:00 PM Central Standard Time, including necessary documentation such as a signed SF1449 form and a Buy American Act certificate. For further inquiries, vendors can contact Sarah Fry at sarah.fry2@va.gov or call 913-758-9935.
    6505--Verapamil Hydrochloride (HCL) Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting offers for the procurement of Verapamil Hydrochloride (HCL) Tablets, aimed at establishing a contract for the supply of this pharmaceutical product through the VA and Department of Defense Pharmaceutical Prime Vendor Programs. The solicitation requires compliance with current Good Manufacturing Practices (cGMP) and mandates a unique National Drug Code (NDC) for each product offered, ensuring adherence to FDA regulations and drug supply chain security measures. Interested contractors must submit their proposals by December 31, 2024, at 2:30 PM CST, and can direct inquiries to Contract Specialist Nicholas I. McGregor at Nicholas.McGregor@va.gov for further information.
    6505--Cyclobenzaprine Tablets (VA-25-00015093)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Cyclobenzaprine HCL Tablets under solicitation number 36E79725R0009. This unrestricted procurement aims to secure a reliable supply of these essential pharmaceuticals for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), reflecting the government's commitment to providing necessary medications to veterans and associated healthcare systems. The contract will have an initial duration of one year, with the possibility of four additional one-year extensions, and interested vendors must provide specific drug labeling along with a unique National Drug Code (NDC). The RFP is expected to be released electronically around December 20, 2024, with a submission deadline set for January 3, 2025. For further inquiries, interested parties can contact Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    6505--Tamsulosin Capsules
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0011 concerning the procurement of Tamsulosin Hydrochloride (HCL) Capsules. This procurement aims to ensure an uninterrupted supply of Tamsulosin HCL for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and other federal healthcare facilities, with one contract awarded to a responsible offeror capable of meeting these needs over a base period of one year, plus four optional one-year extensions. The estimated annual requirements include approximately 1.4 million bottles of 90-count Tamsulosin HCL 0.4mg capsules, along with options for larger packaging sizes, highlighting the importance of consistent medicinal supply for veteran healthcare. Interested vendors should note that the solicitation will be released electronically on or about January 7, 2025, with responses due by January 21, 2025; inquiries can be directed to Contract Specialist Andrew Cazares at Andrew.Cazares@va.gov or (708) 786-4990.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    6505--Abiraterone Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Abiraterone Acetate Tablets through its Pharmaceutical Prime Vendor Program. Offerors are required to comply with the Drug Supply Chain Security Act (DSCSA) and Good Manufacturing Practices (cGMP), providing a unique 11-digit National Drug Code (NDC) for each drug, along with pricing for the base year and four optional years, including a Cost Recovery Fee. This procurement is crucial for ensuring consistent availability and competitive pricing of essential medications for federal healthcare users, particularly veterans. Interested parties must submit their proposals by the extended deadline of January 8, 2025, at 2:30 PM CST, and can contact Contract Specialist Richard Mahario at Richard.Mahario@va.gov for further information.
    6509--Warfarin Tablets (VA-25-00012328)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking proposals for the supply of Warfarin NA tablets under solicitation number VA-25-00012328. The objective of this procurement is to establish a reliable supply contract for Warfarin tablets to ensure consistent availability and pricing through the VA and Department of Defense's Pharmaceutical Prime Vendor Programs. This initiative is crucial for maintaining a steady supply of essential pharmaceuticals, thereby supporting the government’s commitment to high-quality patient care and regulatory compliance. Interested offerors must submit their proposals by December 31, 2024, at 2:30 PM CST, and should direct any inquiries to Contracting Officer Adrienne A Albachiara at Adrienne.Albachiara@va.gov.
    Chlorhexidine Gluconate (CHG) Applicators, Procedural
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking to establish a Qualified Suppliers Listing (QSL) for Chlorhexidine Gluconate (CHG) Applicators, Procedural, intended for use by Military Treatment Facilities (MTFs) across various branches of the U.S. military. Vendors interested in participating must submit a QSL Package Worksheet that demonstrates compliance with stringent requirements, including TAA compliance, sterility, and FDA regulations, as well as provide detailed product specifications and documentation. The estimated annual sales volume for these products is approximately $812,276, based on historical usage data, with the QSL expected to be finalized by February 7, 2025. Interested vendors must ensure their submissions are received by January 9, 2025, and can direct inquiries to Ms. Andrea Honesto at andrea.l.honesto.ctr@health.mil or Mr. David Sheaffer at david.v.sheaffer.ctr@mail.mil.
    6505--Baclofen Tablets (VA-25-00026620)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) 36E79725R0015 for the procurement of Baclofen Tablets, aimed at ensuring a reliable supply for various federal health facilities, including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The procurement will cover a one-year contract with four additional pre-priced option years, requiring offerors to provide products labeled with their unique National Drug Code (NDC) numbers. This initiative is critical for maintaining uninterrupted access to essential medications for veterans and other federal health service users. Interested suppliers should note that the solicitation will be electronically posted on or around December 30, 2024, with a submission deadline of January 13, 2025; inquiries can be directed to Contract Specialist Adrienne A. Albachiara at adrienne.albachiara@va.gov.
    6505--Carbidopa/Levodopa SA Tablet
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) 36E79725R0008 for the procurement of Carbidopa/Levodopa sustained release (SA) tablets, aimed at ensuring a continuous supply of these medications for various federal health services, including the Department of Defense and the Bureau of Prisons. The contract will be awarded for an initial period of one year, with the option to extend for four additional one-year periods, requiring offerors to provide unique branding and packaging without overlapping labels. The estimated annual usage totals approximately 119,875 bottles across two dosage forms, highlighting the importance of these medications in treating Parkinson's disease and related conditions. Interested parties should note that the electronic solicitation is expected to be issued around January 3, 2026, with offers due by January 17, 2026; questions can be directed to the contracting officer, Chris Carthron, at Christopher.Carthron@va.gov.